HHM Wealth Advisors LLC Has $83,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

HHM Wealth Advisors LLC grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 166.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,232 shares of the company’s stock after purchasing an additional 770 shares during the period. HHM Wealth Advisors LLC’s holdings in AstraZeneca were worth $83,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Clearstead Advisors LLC increased its position in shares of AstraZeneca by 15.5% during the third quarter. Clearstead Advisors LLC now owns 1,209 shares of the company’s stock worth $82,000 after acquiring an additional 162 shares in the last quarter. Bryn Mawr Capital Management LLC increased its position in shares of AstraZeneca by 0.3% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 61,866 shares of the company’s stock worth $4,167,000 after acquiring an additional 164 shares in the last quarter. Center for Financial Planning Inc. increased its position in shares of AstraZeneca by 32.9% during the third quarter. Center for Financial Planning Inc. now owns 671 shares of the company’s stock worth $45,000 after acquiring an additional 166 shares in the last quarter. Gradient Investments LLC increased its position in shares of AstraZeneca by 2.4% during the third quarter. Gradient Investments LLC now owns 7,259 shares of the company’s stock worth $492,000 after acquiring an additional 169 shares in the last quarter. Finally, Drive Wealth Management LLC increased its position in shares of AstraZeneca by 4.5% during the fourth quarter. Drive Wealth Management LLC now owns 3,911 shares of the company’s stock worth $263,000 after acquiring an additional 170 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.2 %

AZN stock opened at $75.17 on Monday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $75.81. The stock has a fifty day moving average of $67.27 and a 200-day moving average of $66.05. The company has a market capitalization of $233.06 billion, a price-to-earnings ratio of 36.85, a PEG ratio of 1.37 and a beta of 0.50. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.70 and a current ratio of 0.89.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.01). AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The business had revenue of $12.02 billion during the quarter, compared to the consensus estimate of $12.07 billion. During the same period last year, the business posted $0.69 earnings per share. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. As a group, equities research analysts predict that AstraZeneca PLC will post 4.01 earnings per share for the current year.

AstraZeneca Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Monday, March 25th. Shareholders of record on Friday, February 23rd were issued a $0.965 dividend. This represents a yield of 2.3%. This is an increase from AstraZeneca’s previous Semi-Annual dividend of $0.47. The ex-dividend date of this dividend was Thursday, February 22nd. AstraZeneca’s dividend payout ratio (DPR) is presently 94.61%.

Analyst Upgrades and Downgrades

AZN has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Jefferies Financial Group downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. BMO Capital Markets upped their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Morgan Stanley initiated coverage on shares of AstraZeneca in a research report on Tuesday, January 23rd. They issued an “overweight” rating for the company. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $81.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.